Thankyou very much for this explanation Dr T
I knew also that it was complicated - I recall impression that they were in effect placing the Doxyrubicin in a sort of ‘shroud ‘ - complicated drug delivery system .
For the aim of getting the Doxyrubicin directly more to the cancer cells more , or to seek to bypass the highly deleterious cardiac and other malignant effects .
* To ‘Only ‘ have the Doxyrubicin attack and kill the cancer cells, more - rather than be damaging to human good tissue cells .
But it sounded whacky and fraught to me .
I had not regarded it too much then , as it seemed so extraordinary , & complex design .
And is experimental , and more points to how motivated they are to try to keep doxyrubicin in existence as major drug , rather than have it completely lose favour.
**All to justify Doxyrubicin ongoing , when heart damage cannot and neither should it be ! , anymore ignored .
It is unacceptable already , and oncologists reluctantly have been turning away from Doxyrubicin even though in their hands it has been very good at knocking down a bulk of the cancer in treatment.
Mainly - doxyrubicin has hugely helped to save the patients life .
At least initially... “But .
‘ Longterm heart failure is a pretty big ‘But ‘
Children cannot tolerate it - kills them .
Their heats not strong enough to begin with.
It is sad also - to see a rising incidence of cancers in children . Increasing rates of children’s cancers - reported today in major news .
Not good to hear of bad side effects of this new development drug though - but they have introduced another layer of complexity to try to mitigate effects of a nasty drug with doxyrubicin here .
The chemotherapy drug is only one part in saving the patients lives !
No 1 should be - seek to not harm the patient .
“Above all - Do No Harm “. It’s the no 1 principle in medicine and health. Or should be !
If there is better other alternative- which could be simple to substitute in many cancers - or can be found that exists , then this changes the equation .
Bisantrene is safer in terms of cardiac muscle non- toxicity , and has an advanced pre- history .
Over 40 clinical trials already . Huge amount of data for Bisantrene .
The liposomal Doxyrubicin trials are not as advanced at all as Bisantrene has been .
Your explanations and education as ever , are very much appreciated.
General Comments / Chat, page-88
- There are more pages in this discussion • 10,794 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.31 |
Change
0.020(1.55%) |
Mkt cap ! $217.2M |
Open | High | Low | Value | Volume |
$1.31 | $1.31 | $1.26 | $71.25K | 55.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200 | $1.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 5950 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 1.265 |
3 | 4243 | 1.260 |
2 | 1994 | 1.250 |
2 | 8434 | 1.245 |
2 | 15000 | 1.240 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 5950 | 3 |
1.350 | 1824 | 1 |
1.400 | 44847 | 8 |
1.440 | 20000 | 1 |
1.500 | 7756 | 3 |
Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
Last
$1.31 |
  |
Change
0.020 ( 2.18 %) |
|||
Open | High | Low | Volume | ||
$1.30 | $1.31 | $1.26 | 10789 | ||
Last updated 15.59pm 26/04/2024 ? |
Featured News
RAC (ASX) Chart |